There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Stemline Therapeutics Inc (NASDAQ:STML) and Viveve Medical Inc (NASDAQ:VIVE) with bullish sentiments.
Stemline Therapeutics Inc (STML)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Stemline Therapeutics Inc, with a price target of $38. The company’s shares closed yesterday at $15.
Selvaraju noted:
“Our 12-month price target is derived from a discounted cash flow-based asset value of $1.1B for 15% discount rate and 2% terminal growth rate. Probabilities of success ascribed to SL-401 and SL-701 are 90% and 45%, respectively. Risks include, but are not limited to: (1) failure of drug candidates in clinical trials; (2) failure of drug candidates to secure regulatory approval; (3) failure of drug candidates to achieve commercial success due to market size, penetration rate, and/or competition; and (4) potential medium-term dilution risk.”
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -1.7% and a 36.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Stemline Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $34.
See today’s analyst top recommended stocks >>
Viveve Medical Inc (VIVE)
Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Viveve Medical Inc today and set a price target of $9. The company’s shares closed yesterday at $2.47, close to its 52-week low of $1.60.
Vendetti commented:
“Market close, VIVE reported 2Q18 revenue inline with the preannouncement and relatively inline GAAP EPS. VIVE reiterated its 2018 revenue guidance of $22M-$24M and gross margins are expected to expand due to higher ASPs. The FDA approved the expansion of the VIVEVE II study to 100 patients, but required additional safety data from the first 50 patients before potentially allowing full enrollment. We estimate that this will delay the regulatory timeline by approximately two months.”
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 9.3% and a 54.0% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Xtant Medical Holdings.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viveve Medical Inc with a $6.75 average price target, implying a 173.3% upside from current levels. In a report issued on July 31, Mizuho Securities also maintained a Buy rating on the stock with a $4 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
